# GEOMed360

> Generative Engine Optimization (GEO) consultancy for pharmaceutical and life sciences companies. Tagline: "Winning the answer" — SEO was about winning the click; GEO is about winning the answer, meaning being the source AI systems cite. GEOMed360 publishes its full research openly on this site; the complete content is available in one file at https://geomed360.com/llms-full.txt.

GEOMed360 helps pharmaceutical companies, biotech firms, and medical affairs teams achieve accurate and consistent visibility in AI-generated responses from large language models (ChatGPT, Claude, Gemini, Perplexity, Google AI Overviews, and specialized clinical AI platforms). It was founded at the convergence of deep pharmaceutical expertise — medical information, medical affairs, pharma digital strategy — and hands-on generative AI practice. GEOMed360's research is grounded in a proprietary multi-model, dual-persona audit programme across oncology, cardiometabolic disease, and interstitial lung disease (2025–2026).

## Services

GEOMed360 works ad-hoc and tailored — no standard packages. Every engagement is shaped around the client organisation's starting point, therapeutic priorities, and pace.

- [GEO Foundations](https://geomed360.com/#services): An intensive, tailored team-enablement session (half-day or full-day) that builds GEO understanding from within pharma teams, aligned to their therapeutic areas and digital maturity. Covers GEO fundamentals, LLM behavior in healthcare contexts, regulatory implications, live demos with the client's own therapeutic-area queries, and practical first steps. Suitable for medical affairs, digital health, commercial, and regulatory audiences.

- [GEO Partnership](https://geomed360.com/#services): An ongoing embedded partnership where GEOMed360 works alongside pharma teams — joining planning cycles, reviewing content, guiding implementation, and iterating as the AI landscape evolves. GEOMed360 installs the in-house GEO capability described in its research, runs the first cycles jointly, and transfers every asset so the capability and its intellectual property stay in-house.

## Research: the GEOMed360 whitepaper

"Winning the Answer: Generative Engine Optimization as a Strategic Imperative for the Pharmaceutical Industry" (July 2026) is published in full on the site — no download gate. Start at the hub:

- [Winning the Answer — executive summary and chapter index](https://geomed360.com/winning-the-answer.html): Executive summary, five key findings, and the complete 26-item reference list.

Chapters:
- [The great rewiring of health information discovery](https://geomed360.com/great-rewiring-health-information.html): How AI answers replaced ranked links in health information: click-through collapse, physician and patient adoption of AI assistants, and what it means for pharma digital strategy.
- [Why pharmaceutical companies are uniquely exposed](https://geomed360.com/why-pharma-is-uniquely-exposed.html): Four structural features that make pharma's exposure to AI-mediated information qualitatively different: regulatory asymmetry, dual audiences, machine-hostile legacy content, and hallucination risk.
- [Inside the machine: how generative engines select evidence](https://geomed360.com/how-generative-engines-select-evidence.html): The three technical layers behind AI answers — LLMs, semantic search, and retrieval-augmented generation — and the peer-reviewed evidence on which GEO tactics actually move AI visibility.
- [Field evidence: what multi-model audits actually reveal](https://geomed360.com/geo-field-evidence-pharma.html): Five findings from GEOMed360's multi-model, dual-persona audit programme across oncology, cardiometabolic and interstitial lung disease assets: citation mix, format effects, systematic errors, persona gaps, and model heterogeneity.
- [The GEO operating framework: tiers, lifecycle, and the PICO standard](https://geomed360.com/geo-operating-framework-pharma.html): A GEO operating framework for pharma: the three-tier content architecture, lifecycle sequencing from clinical development to post-launch, and the PICO standard for machine-readable claims.
- [Standing up the capability: building GEO in-house](https://geomed360.com/building-geo-capability-in-house.html): How pharmaceutical companies build an internal GEO capability: the build-and-transfer principle, pilot sequencing, cross-functional governance, the three-phase service workflow, ownership matrix, and compliance-aware operating rules.
- [Recommendations: the agenda for pharmaceutical leaders](https://geomed360.com/geo-recommendations-pharma-leaders.html): Five GEO workstreams for pharma leaders: establishing the baseline, restructuring the content estate, managing the source ecosystem, building organizational capability, and governing and measuring — from a 90-day agenda to enterprise commitment.
- [Measuring what matters: the new KPI stack — and the road ahead](https://geomed360.com/measuring-geo-and-the-road-ahead.html): The four-layer GEO measurement architecture for pharma — visibility, accuracy, ecosystem health, business linkage — plus the three developments shaping the next 36 months and the GEOMed360 audit methodology.

## Key Concepts and Definitions

- **Winning the Answer**: GEOMed360's tagline and the goal of GEO. Traditional SEO competed for the click (a ranked position on a search results page); GEO competes for the answer itself — being the source an AI assistant cites and accurately represents when responding to questions in a given domain.
- **GEO (Generative Engine Optimization)**: Optimizing content and digital presence for AI citation rather than search engine rankings. Formalized in a 2024 peer-reviewed study (KDD 2024) showing content interventions raise AI-answer visibility by up to 40 percent.
- **LLMs.txt**: A plain-text file at the root of a website (similar in concept to robots.txt) that helps AI systems understand the site's purpose, key content, and how to represent it accurately. The expanded full-content version of this file is at https://geomed360.com/llms-full.txt.
- **Three-tier content architecture**: GEOMed360's framework assigning AI-relevant pharma content to Tier 1 (the truth engine: labels, registries, publications, guidelines), Tier 2 (narrative hubs: owned websites and portals), and Tier 3 (the amplification layer: social, forums, news).
- **PICO standard**: Converting narrative efficacy claims into Population–Intervention–Comparator–Outcome structured statements with explicit statistics, confidence intervals and co-located safety context — pre-approvable by medical-legal-regulatory review as a production format.
- **Dual-persona audit**: GEOMed360's method of testing AI answers with separate healthcare-professional and patient prompt framings across multiple large language models, scoring accuracy, completeness, safety framing and citation quality.

## Primary Audience

- Medical affairs professionals in pharma and biotech
- Digital health and digital strategy teams in life sciences
- Communications and external affairs functions
- Commercial and brand teams in pharmaceutical companies
- Regulatory and compliance stakeholders with digital responsibilities

## Contact

- Website: https://geomed360.com
- Email: hello@geomed360.com
- Engagements: Scoped ad-hoc, always starting with a conversation via email

## Optional

- [Complete site content in one file](https://geomed360.com/llms-full.txt)
- [FAQ](https://geomed360.com/#faq): Common questions about GEO in pharma and life sciences
- [How we work](https://geomed360.com/#services): GEOMed360's ad-hoc, embedded partnership model